Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi
Abstract
Aim: This study indirectly compared the effectiveness of pembrolizumab monotherapy versus nivolumab + ipilimumab in metastatic non-small-cell lung cancer. Materials and methods: A matching-adjusted indirect comparison was conducted using pooled individual patient data from KEYNOTE-024 and KEYNOTE-042 and published aggregate data from CheckMate 227 Part 1A, with platinum doublet chemotherapy as the anchor. Results: After matching, estimated hazard ratios (95% CI) of pembrolizumab monotherapy versus nivolumab + ipilimumab for overall survival and progression-free survival were 1.07 (0.82, 1.39) and 1.16 (0.93, 1.45), respectively. For objective response rate, the estimated risk ratio (95% CI) was 0.93 (0.71, 1.22) and the risk difference (95% CI) was -2.86%(-11.38, 5.67). Conclusion: Matching-adjusted indirect comparison results demonstrated comparable effectiveness between pembrolizumab monotherapy and nivolumab + ipilimumab as first-line therapies for metastatic non-small-cell lung cancer with PD-L1 tumor-proportion score ≥1%.
Trial registration: ClinicalTrials.gov NCT02142738 NCT02220894.
Keywords: comparative effectiveness; nivolumab; non-small-cell lung cancer; pembrolizumab.
Source: PubMed